Abstract
We read with great interest the article by Wakabayashi et al1 recently published in Circulation: Cardiovascular Interventions . Wakabayashi et al reviewed the mechanisms of edge restenosis, bringing insights into the possible underlying causes of this phenomenon analyzing results from several drug-eluting stent (DES) trials. They suggest that the principal mechanism of edge restenosis in bare metal stent as in DES is through plaque shift and intimal hyperplasia proliferation beyond the stent edges, within the first millimeter from the stent. Interestingly, the authors noted from several trials, including paclitaxel-, sirolimus-, zotarolimus-, and everolimus-eluting stents that despite significant reduction in restenosis with DES compared with bare metal stent control, …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
